埃克替尼致1例肺癌患者纯红细胞再生障碍性贫血的分析与药学监护

Analysis and Pharmaceutical Care of Pure Red Cell Aplastic Anemia Caused by Icotinib in a Patient with Lung Cancer

埃克替尼为晚期肺癌的一线用药,常见药品不良反应为皮疹、腹泻等,纯红细胞再生障碍性贫血(PRCA)为埃克替尼新的、严重的不良反应。临床药师参与1例肺癌患者应用埃克替尼后出现PRCA的治疗过程,详细分析了发生PRCA的可能原因,并对患者开展药学监护,旨在提高临床医生和药师对该类不良反应的警惕。

Icotinib is the first⁃line drug for advanced lung cancer.Its common adverse drug reactions are rash and diarrhea,and pure red cell aplastic anemia(PRCA)is a new and serious adverse reaction.Clinical pharmacists participa⁃ted in the treatment of PRCA in a patient with lung cancer who was treated with icotinib.The possible causes of PRCA were analyzed in detail,and the patient was given whole⁃process pharmaceutical care,aiming to improve the vigilance of clini⁃cians and pharmacists on PRCA.